{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:09:37Z","timestamp":1792465777939,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ajt.2026.02.024","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:06:32Z","timestamp":1772557592000},"page":"1946-1957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Expert consensus on the use of immune checkpoint inhibitors in the liver transplant setting: Guidance from the Liver Transplant Committee of the Italian Association for the Study of the Liver (AISF)"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5924-6238","authenticated-orcid":false,"given":"Francesca Romana","family":"Ponziani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4079-7974","authenticated-orcid":false,"given":"Valerio","family":"Giannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-3948","authenticated-orcid":false,"given":"Giuseppe","family":"Marrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-5538","authenticated-orcid":false,"given":"Silvia","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9742-1981","authenticated-orcid":false,"given":"Maria Cristina","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3987-9262","authenticated-orcid":false,"given":"Duilio","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4399-3359","authenticated-orcid":false,"given":"Gianluca Svegliati","family":"Baroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4332-2072","authenticated-orcid":false,"given":"Giacomo","family":"Germani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-191X","authenticated-orcid":false,"given":"Patrizia","family":"Burra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2566-3041","authenticated-orcid":false,"given":"Pierluigi","family":"Toniutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ajt.2026.02.024_bib1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"10126","key":"10.1016\/j.ajt.2026.02.024_bib2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"10064","key":"10.1016\/j.ajt.2026.02.024_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ajt.2026.02.024_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ajt.2026.02.024_bib5","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ajt.2026.02.024_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"10492","key":"10.1016\/j.ajt.2026.02.024_bib7","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ajt.2026.02.024_bib8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib9","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ajt.2026.02.024_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ajt.2026.02.024_bib11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1148\/radiol.12121698","article-title":"New OPTN\/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma","volume":"266","author":"Wald","year":"2013","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib12","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.cgh.2022.02.018","article-title":"UNOS down-staging criteria for liver transplantation of hepatocellular carcinoma: systematic review and meta-analysis of 25 studies","volume":"21","author":"Tan","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ajt.2026.02.024_bib13","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver transplantation for hepatocellular carcinoma: a model including \u03b1-fetoprotein improves the performance of Milan criteria","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ajt.2026.02.024_bib14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib15","first-page":"743","article-title":"The concept of \u201cconverse therapeutic hierarchy\u201d for patients with hepatocellular carcinoma","volume":"14","author":"Vitale","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ajt.2026.02.024_bib16","doi-asserted-by":"crossref","unstructured":"Vitale A, Kim JS, Cabibbo G, et al. Conversion ability of immunotherapy in hepatocellular carcinoma: insights from the international converse study. Liver Cancer. Published online August 5, 2025. https:\/\/doi.org\/10.1159\/000547792.","DOI":"10.1159\/000547792"},{"issue":"4","key":"10.1016\/j.ajt.2026.02.024_bib17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jhep.2024.01.010","article-title":"Merits and boundaries of the BCLC staging and treatment algorithm: learning from the past to improve the future with a novel proposal","volume":"80","author":"Trevisani","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajt.2026.02.024_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1091088","article-title":"Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma","volume":"12","author":"Peng","year":"2023","journal-title":"Front Oncol"},{"issue":"S1","key":"10.1016\/j.ajt.2026.02.024_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12072-017-9808-z","article-title":"New concepts on the clinical course and stratification of compensated and decompensated cirrhosis","volume":"12","author":"D\u2019Amico","year":"2018","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.ajt.2026.02.024_bib20","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/ajt.15617","article-title":"Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?","volume":"20","author":"Nordness","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ajt.2026.02.024_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101386","article-title":"Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period","volume":"66","author":"Chen","year":"2021","journal-title":"Transpl Immunol"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib22","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s12328-021-01521-4","article-title":"Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy","volume":"14","author":"Dehghan","year":"2021","journal-title":"Clin J Gastroenterol"},{"issue":"7001","key":"10.1016\/j.ajt.2026.02.024_bib23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/bmj.311.7001.376","article-title":"Qualitative research: consensus methods for medical and health services research","volume":"311","author":"Jones","year":"1995","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.ajt.2026.02.024_bib24","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/ACM.0000000000001812","article-title":"The use of the Delphi and other consensus group methods in medical education research: a review","volume":"92","author":"Humphrey-Murto","year":"2017","journal-title":"Acad Med"},{"issue":"4_Suppl","key":"10.1016\/j.ajt.2026.02.024_bib25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2025.43.4_suppl.573","article-title":"Clinical outcome after complete response with immunotherapy in hepatocellular carcinoma","volume":"43","author":"Chen","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ajt.2026.02.024_bib26","article-title":"Liver resection and transplantation in the era of checkpoint inhibitors","volume":"6","author":"Tabrizian","year":"2024","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib27","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1097\/HEP.0000000000001163","article-title":"Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy","volume":"81","author":"Scheiner","year":"2025","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ajt.2026.02.024_bib28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.ajt.2026.02.024_bib29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2024.05.037","article-title":"Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation","volume":"81","author":"Li","year":"2024","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib30","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1097\/TP.0000000000004108","article-title":"The impact of treatment of hepatocellular carcinoma with immune checkpoint inhibitors on pre- and post-liver transplant outcomes","volume":"106","author":"Dave","year":"2022","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.ajt.2026.02.024_bib31","doi-asserted-by":"crossref","first-page":"9354","DOI":"10.21037\/apm-21-999","article-title":"Prognosis after liver transplantation in patients treated with anti-PD-1 immunotherapy for advanced hepatocellular carcinoma: case series","volume":"10","author":"Chen","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.ajt.2026.02.024_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.653437","article-title":"Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review","volume":"12","author":"Qiao","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib33","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/LVT.0000000000000083","article-title":"Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss","volume":"29","author":"Wang","year":"2023","journal-title":"Liver Transpl"},{"issue":"2","key":"10.1016\/j.ajt.2026.02.024_bib34","article-title":"Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma","volume":"7","author":"Tabrizian","year":"2025","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.ajt.2026.02.024_bib35","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/ajt.16448","article-title":"PD-1 inhibitor as bridge therapy to liver transplantation?","volume":"21","author":"Tabrizian","year":"2021","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2026.02.024_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis","volume":"82","author":"Rezaee-Zavareh","year":"2025","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ajt.2026.02.024_bib37","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","article-title":"Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study","volume":"82","author":"Tabrizian","year":"2025","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ajt.2026.02.024_bib38","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/HEP.0000000000001289","article-title":"Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: an international retrospective cohort study","volume":"82","author":"Moeckli","year":"2025","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.ajt.2026.02.024_bib39","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ajt.2024.04.007","article-title":"Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: a multicenter, retrospective cohort study","volume":"24","author":"Guo","year":"2024","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2026.02.024_bib40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.livres.2025.03.001","article-title":"Short-term prognosis of recipients with pretransplant exposure to immune checkpoint inhibitors after liver transplantation for hepatocellular carcinoma: a retrospective cohort study","volume":"9","author":"Pang","year":"2025","journal-title":"Liver Res"},{"issue":"Pt 2","key":"10.1016\/j.ajt.2026.02.024_bib41","article-title":"Risk of transplant rejection associated with ICIs prior to liver transplantation in HCC: a multicenter retrospective study","volume":"143","author":"Xu","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.ajt.2026.02.024_bib42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00262-024-03853-9","article-title":"Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation","volume":"74","author":"Lu","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ajt.2026.02.024_bib43","doi-asserted-by":"crossref","unstructured":"Fang J, Zhong S, Wang T, et al. Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study. Gut. Published online November 4, 2025:gutjnl-2025-336719. doi:10.1136\/gutjnl-2025-336719.","DOI":"10.1136\/gutjnl-2025-336719"},{"issue":"10","key":"10.1016\/j.ajt.2026.02.024_bib44","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.1097\/JS9.0000000000001813","article-title":"Pembrolizumab in combination with lenvatinib in participants with hepatocellular carcinoma before liver transplant as neoadjuvant TherapY-PLENTY pilot study","volume":"110","author":"Lv","year":"2024","journal-title":"Int J Surg"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib45","first-page":"815","article-title":"The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma","volume":"31","author":"Kodali","year":"2025","journal-title":"Liver Transpl"},{"issue":"3","key":"10.1016\/j.ajt.2026.02.024_bib46","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s13304-024-01845-z","article-title":"Immunosuppression in liver transplant oncology: position paper of the Italian Board of Experts in Liver Transplantation (I-BELT)","volume":"76","author":"Cillo","year":"2024","journal-title":"Update Surg"},{"issue":"1","key":"10.1016\/j.ajt.2026.02.024_bib47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000520278","article-title":"First-line immune checkpoint inhibitor-based sequential therapies for advanced hepatocellular carcinoma: rationale for future trials","volume":"11","author":"Cabibbo","year":"2022","journal-title":"Liver Cancer"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib48","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000541018","article-title":"Lenvatinib versus sorafenib second-line therapy in patients with hepatocellular carcinoma progressed to atezolizumab plus bevacizumab: a retrospective real-world study","volume":"103","author":"Persano","year":"2024","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.ajt.2026.02.024_bib49","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/hep.22412","article-title":"Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis","volume":"48","author":"Yao","year":"2008","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.ajt.2026.02.024_bib50","first-page":"779","article-title":"Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma","volume":"157","author":"Tabrizian","year":"2022","journal-title":"JAMA Surg"},{"issue":"7","key":"10.1016\/j.ajt.2026.02.024_bib51","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","article-title":"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial","volume":"21","author":"Mazzaferro","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ajt.2026.02.024_bib52","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10.1016\/j.ajt.2026.02.024_bib53","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ajt.2026.02.024_bib54","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1097\/JS9.0000000000001104","article-title":"Risk assessment in liver transplantation for hepatocellular carcinoma: long-term follow-up of a two-centre experience","volume":"110","author":"Wehrle","year":"2024","journal-title":"Int J Surg"},{"issue":"3","key":"10.1016\/j.ajt.2026.02.024_bib55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.57603\/EJT-1569","article-title":"Pre-transplant assessment of the HCC recurrence risk","author":"Fedele","year":"2025","journal-title":"Eur J Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2026.02.024_bib56","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/LVT.0000000000000145","article-title":"Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: analysis of the US Multicenter HCC Transplant Consortium","volume":"29","author":"Tran","year":"2023","journal-title":"Liver Transpl"},{"issue":"12","key":"10.1016\/j.ajt.2026.02.024_bib57","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1111\/tri.14159","article-title":"The RETREAT score provides valid predictions regarding hepatocellular carcinoma recurrence after liver transplantation","volume":"34","author":"\u00c5berg","year":"2021","journal-title":"Transpl Int"},{"issue":"1","key":"10.1016\/j.ajt.2026.02.024_bib58","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1038\/s41467-025-59745-8","article-title":"Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria","volume":"16","author":"Ling","year":"2025","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib59","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jhep.2016.02.034","article-title":"Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction","volume":"64","author":"Shi","year":"2016","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.ajt.2026.02.024_bib60","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/tri.13621","article-title":"HCC recurrence in HCV-infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs\u2014a post-hoc analysis","volume":"33","author":"Werner","year":"2020","journal-title":"Transpl Int"},{"issue":"1","key":"10.1016\/j.ajt.2026.02.024_bib61","doi-asserted-by":"crossref","DOI":"10.5500\/wjt.v14.i1.88833","article-title":"Liver transplantation for hepatocellular carcinoma in India: are we ready for 2040?","volume":"14","author":"Pahari","year":"2024","journal-title":"World J Transplant"},{"issue":"28","key":"10.1016\/j.ajt.2026.02.024_bib62","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.3748\/wjg.v30.i28.3452","article-title":"Impact of neoadjuvant multimodal therapy in the setting of locally advanced hepatocellular carcinoma","volume":"30","author":"Ferraro","year":"2024","journal-title":"World J Gastroenterol"},{"issue":"8","key":"10.1016\/j.ajt.2026.02.024_bib63","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1016\/j.transproceed.2013.08.068","article-title":"Risk-based long-term screening for hepatocellular carcinoma recurrence after living donor liver transplantation","volume":"45","author":"Hwang","year":"2013","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib64","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/HEP.0000000000001297","article-title":"A prospective multicenter validation of RETREAT for posttransplantation HCC recurrence prediction","volume":"82","author":"Li","year":"2025","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ajt.2026.02.024_bib65","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2016.5116","article-title":"Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant","volume":"3","author":"Mehta","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ajt.2026.02.024_bib66","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3390\/cancers14030630","article-title":"External validation of the RETREAT score for prediction of hepatocellular carcinoma recurrence after liver transplantation","volume":"14","author":"Van Hooff","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ajt.2026.02.024_bib67","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/SLA.0000000000001426","article-title":"Systematic review and meta-analysis of current experience in treating IPNB: clinical and pathological correlates","volume":"263","author":"Gordon-Weeks","year":"2016","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib68","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cgh.2017.11.037","article-title":"Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within Milan criteria: a multicenter study","volume":"16","author":"Mehta","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.ajt.2026.02.024_bib69","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1600-6143.2008.02409.x","article-title":"Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria","volume":"8","author":"Ravaioli","year":"2008","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib70","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.27752","article-title":"Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria","volume":"61","author":"Yao","year":"2015","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.ajt.2026.02.024_bib71","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ctr.12755","article-title":"Predictive factors for extrahepatic recurrence of hepatocellular carcinoma following liver transplantation","volume":"30","author":"Andreou","year":"2016","journal-title":"Clin Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2026.02.024_bib72","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jhep.2012.03.022","article-title":"Liver transplantation for unresectable hepatocellular carcinoma in normal livers","volume":"57","author":"Mergental","year":"2012","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ajt.2026.02.024_bib73","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/jso.21415","article-title":"Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma","volume":"101","author":"Lee","year":"2010","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.ajt.2026.02.024_bib74","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2016.10.038","article-title":"Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC","volume":"66","author":"Notarpaolo","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib75","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/TP.0000000000003175","article-title":"The ILTS consensus conference on transplant oncology: setting the stage","volume":"104","author":"Sapisochin","year":"2020","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.ajt.2026.02.024_bib76","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.dld.2009.09.002","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal","volume":"42","author":"Trevisani","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.ajt.2026.02.024_bib77","doi-asserted-by":"crossref","first-page":"192","DOI":"10.21037\/hbsn-22-33","article-title":"Prognostication algorithm for non-cirrhotic non-B non-C hepatocellular carcinoma\u2014a multicenter study under the aegis of the French Association of Hepato-Biliary Surgery and liver Transplantation","volume":"12","author":"Maulat","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"4","key":"10.1016\/j.ajt.2026.02.024_bib78","article-title":"New frontiers in liver resection for hepatocellular carcinoma","volume":"2","author":"Allaire","year":"2020","journal-title":"JHEP Rep"},{"issue":"12","key":"10.1016\/j.ajt.2026.02.024_bib79","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.ajt.2026.02.024_bib80","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajt.2026.02.024_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.liver.2024.100256","article-title":"Immunotherapy in liver transplantation for hepatocellular carcinoma: a comprehensive review","volume":"17","author":"Akabane","year":"2025","journal-title":"J Liver Transpl"},{"issue":"11","key":"10.1016\/j.ajt.2026.02.024_bib82","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.3390\/jcm13113068","article-title":"Utilization of immunotherapy as a neoadjuvant therapy for liver transplant recipients with hepatocellular carcinoma","volume":"13","author":"Abdelrahim","year":"2024","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib83","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s10238-022-00938-6","article-title":"Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis","volume":"23","author":"Tian","year":"2023","journal-title":"Clin Exp Med"},{"issue":"2","key":"10.1016\/j.ajt.2026.02.024_bib84","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ajt.2026.02.024_bib85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.17998\/jlc.2023.11.21","article-title":"Complications of immunotherapy in advanced hepatocellular carcinoma","volume":"24","author":"Song","year":"2023","journal-title":"J Liver Cancer"},{"issue":"1","key":"10.1016\/j.ajt.2026.02.024_bib86","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4251\/wjgo.v14.i1.163","article-title":"Immunotherapy in liver transplantation for hepatocellular carcinoma: pros and cons","volume":"14","author":"Luo","year":"2022","journal-title":"World J Gastrointest Oncol"},{"issue":"21","key":"10.1016\/j.ajt.2026.02.024_bib87","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/ijms252111676","article-title":"Immune checkpoint inhibitors in the pre-transplant hepatocellular carcinoma setting: a glimpse beyond the liver","volume":"25","author":"Marzi","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.ajt.2026.02.024_bib88","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7403","article-title":"Multidisciplinary management of immunotherapy-related adverse events in solid tumors: an inter-institutional and telemedicine-based working team","volume":"13","author":"Iaculli","year":"2024","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.ajt.2026.02.024_bib89","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/liv.15419","article-title":"Immune checkpoint inhibitors in malignancies after liver transplantation: a systematic review and pooled analysis","volume":"43","author":"Kayali","year":"2023","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.ajt.2026.02.024_bib90","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/LVT.0000000000000550","article-title":"Immune checkpoint inhibitors in the posttransplant landscape of HCC: a systematic literature review","volume":"32","author":"Kahramangil","year":"2026","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.ajt.2026.02.024_bib91","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s12672-025-02299-4","article-title":"The safety and efficacy of atezolizumab for recurrent primary liver cancer after liver transplantation","volume":"16","author":"Yao","year":"2025","journal-title":"Discov Oncol"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib92","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jhep.2023.01.030","article-title":"Liver transplantation immunology: immunosuppression, rejection, and immunomodulation","volume":"78","author":"Montano-Loza","year":"2023","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.ajt.2026.02.024_bib93","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.3390\/curroncol31090371","article-title":"Focal update on immunotherapy and liver transplantation in the era of transplant oncology","volume":"31","author":"Abdelrahim","year":"2024","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.ajt.2026.02.024_bib94","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1002\/cam4.5394","article-title":"Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: a safety analysis from a literature review and a pharmacovigilance system","volume":"12","author":"Cui","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ajt.2026.02.024_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1514033","article-title":"PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database","volume":"16","author":"G\u00e9rard","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajt.2026.02.024_bib96","article-title":"Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ajt.2026.02.024_bib97","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/TP.0000000000002955","article-title":"Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation","volume":"104","author":"Invernizzi","year":"2020","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.ajt.2026.02.024_bib98","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/tri.13897","article-title":"High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients","volume":"34","author":"Nitta","year":"2021","journal-title":"Transpl Int"},{"issue":"6","key":"10.1016\/j.ajt.2026.02.024_bib99","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jaad.2019.07.005","article-title":"Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review","volume":"82","author":"Fisher","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ajt.2026.02.024_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2026.02.019","article-title":"Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL)","author":"Bhoori","year":"2026","journal-title":"J. Hepatol."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613526001073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613526001073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:06:10Z","timestamp":1785179170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613526001073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":100,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1600613526001073"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2026.02.024","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert consensus on the use of immune checkpoint inhibitors in the liver transplant setting: Guidance from the Liver Transplant Committee of the Italian Association for the Study of the Liver (AISF)","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2026.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society of Transplantation & American Society of Transplant Surgeons.","name":"copyright","label":"Copyright"}]}}